| Date | Form | Description | Docs | XBRL | Pages |
| 09/09/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
21 |
| 06/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
19 |
| 03/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
19 |
| 09/01/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
20 |
| 06/10/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
23 |
| 03/11/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
30 |
| 09/08/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
37 |
| 06/09/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
60 |
| 03/09/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
Latest News & Events
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Read More...Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Read More...Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Read More...